Oxidative stress and neurodegeneration

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 545-552

  Moreira, Paula I ^a,b   Smith, Mark A ^a   Zhu, Xiongwei ^a   Nunomura, Akihiko ^c   Castellani, Rudy J ^d   Perry, George ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Advanced glycation end products; Alzheimer's disease; Neurofibrillary tangles; Oxidative stress; Senile plaques

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALDEHYDE; HEXITOL LYSINE; LYSINE DERIVATIVE; OXYGEN RADICAL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; GLYCATION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MACROMOLECULE; NERVE CELL; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; OLFACTORY EPITHELIUM; OXIDATIVE STRESS;

EID: 23744439419     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.062     Document Type: Conference Paper

References (50)

1. SMITH, M.A. 1998. Alzheimer disease. Int. Rev. Neurobiol. 42: 1-54.
2. NUNOMURA, A. et al. 1999. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19: 1959-1964.
3. NUNOMURA, A. et al. 2000. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J. Neuropathol. Exp. Neurol. 59: 1011-1017.
4. NUNOMURA, A. et al. 2001. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60: 759-767.
5. SMITH, M.A. et al. 1996. Oxidative damage in Alzheimer's. Nature 382: 120-121.
6. SMITH, M.A. et al. 1997. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17: 2653-2657.
7. CRAS, P. et al. 1995. Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol. (Berl.) 89: 291-295.
8. SAYRE, L.M. et al. 1997. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68: 2092-2097.
9. ZHU, X. et al. 2004. Oxidative stress signalling in Alzheimer's disease. Brain Res. 1000: 32-39.
10. SMITH, M.A. et al. 1994. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA 91: 5710-5714.
11. SMITH, M.A. et al. 1995. Radical AGEing in Alzheimer's disease. Trends Neurosci. 18: 172-176.
12. CASTELLANI, R.J. et al. 2001. Active glycation in neurofibrillary pathology of Alzheimer disease: Nε-(carboxymethyl)lysine and hexitol-lysine. Free Radic. Biol. Med. 31: 175-180.
13. PERRY, G. et al. 2002. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 133: 507-513.
14. SMITH, M.A. et al. 1995. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J. Neurochem. 64: 2660-2666.
15. PERRY, G. et al. 1989. Immunochemical properties of ubiquitin conjugates in the paired helical filaments of Alzheimer disease. J. Neurochem. 52: 1523-1528.
16. GOU, J.P., J. EYER & J.F. LETERRIER. 1995. Progressive hyperphosphorylation of neurofilament heavy subunits with aging: possible involvement in the mechanism of neurofilament accumulation. Biochem. Biophys. Res. Commun. 215: 368-376.
17. FRIGUET, B., E.R. STADTMAN & L.I. SZWEDA. 1994. Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Formation of cross-linked protein that inhibits the multicatalytic protease. J. Biol. Chem. 269: 21639-21643.
18. MAILLARD, L.C. 1912. Action des acides aminés sur les sucres; formation des mélanoidines par voie méthodique. C.R. Acad. Sci. 154: 66-68.
19. HARRINGTON, C.R. & C.A. COLACO. 1994. Alzheimer's disease. A glycation connection. Nature 370: 247-248.
20. LEDESMA, M.D. et al. 1994. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. 269: 21614-21619.
21. MUNCH, G. et al. 1997. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res. Rev. 23: 134-143.
22. THOME, J. et al. 1996. Advanced glycation end products-associated parameters in the peripheral blood of patients with Alzheimer's disease. Life Sci. 59: 679-685.
23. MUNCH, G. et al. 1998. Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J. Neural Transm. 105: 439-461.
24. REDDY, V.P. et al. 2002. Involvement of Maillard reactions in Alzheimer disease. Neurotox. Res. 4: 191-209.
25. VITEK, M.P. et al. 1994. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91: 4766-4770.
26. SHUVAEV, V.V. et al. 2001. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol. Aging 22: 397-402.
27. LI, J.J. et al. 1995. Age-dependent accumulation of advanced glycosylation end products in human neurons. Neurobiol. Aging 16: 69-76.
28. KO, L.W. et al. 1999. An immunochemical study or tau glycation in paired helical filaments. Brain Res. 830: 301-313.
29. VLASSARA, H., M. BROWNLEE & A. CERAMI. 1985. High-affinity-receptor- mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc. Natl. Acad. Sci. USA 82: 5588-5592.
30. VLASSARA, H., R. BUCALA & L. STRIKER. 1994. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70: 138-151.
31. SCHMIDT, A.M. et al. 1994. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J. Biol. Chem. 269: 9882-9888.
32. KISLINGER, T. et al. 1999. Nε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274: 31740-31749.
33. CASTELLANI, R. et al. 1996. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 737: 195-200.
34. CASTELLANI, R.J. et al. 1997. Advanced glycation modification of Rosenthal fibers in patients with Alexander disease. Neurosci. Lett. 231: 79-82.
35. DUNN, J.A. et al. 1991. Age-dependent accumulation of Nε-(carboxymethyl)lysine and Nε-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30: 1205-1210.
36. REDDY, S. et al. 1995. Nε-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878.
37. FU, M.X. et al. 1996. The advanced glycation end product, Nε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271: 9982-9986.
38. SCHLEICHER, E.D., E. WAGNER & A.G. NERLICH. 1997. Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99: 457-468.
39. KUME, S. et al. 1995. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am. J. Pathol. 147: 654-667.
40. MIYATA, T. et al. 1999. 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5- ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett. 445: 202-206.
41. MONTINE, T.J. et al. 1996. E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. Am. J. Pathol. 148: 89-93.
42. PERRY, G. et al. 2003. Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol. (Berl.) 106: 552-556.
43. PEARSON, R.C. et al. 1985. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc. Natl. Acad. Sci. USA 82: 4531-4534.
44. REYES, P.F. et al. 1987. The prepiriform cortex in dementia of the Alzheimer type. Arch. Neurol. 44: 644-645.
45. TALAMO, B.R. et al. 1989. Pathological changes in olfactory neurons in patients with Alzheimer's disease. Nature 337: 736-739.
46. TABATON, M. et al. 1991. Abnormal tau-reactive filaments in olfactory mucosa in biopsy specimens of patients with probable Alzheimer's disease. Neurology 41: 391-394.
47. TROJANOWSKI, J.Q. et al. 1991. Human olfactory epithelium in normal aging, Alzheimer's disease, and other neurodegenerative disorders. J. Comp. Neurol. 310: 365-376.
48. GHANBARI, H.A. et al. 2004. Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell 3: 41-44.
49. SMITH, M.A. et al. 1994. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol. 145: 42-47.
50. PERRY, G. et al. 1998. Reactive oxygen species mediate cellular damage in Alzheimer disease. J. Alzheimers Dis. 1: 45-55.